What is Losartan + Hidroclorotiazida Labesfal?
Losartan + Hidroclorotiazida Labesfal contains a combination of Losartan + Hidroclorotiazida Labesfal. Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention. Losartan (Losartan + Hidroclorotiazida Labesfal) is an angiotensin II receptor antagonist. Losartan (Losartan + Hidroclorotiazida Labesfal) keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow.
Losartan + Hidroclorotiazida Labesfal is used to treat high blood pressure (hypertension). It is also used to lower the risk of stroke in certain people with heart disease.
Losartan + Hidroclorotiazida Labesfal may also be used for purposes not listed in this medication guide.
Losartan + Hidroclorotiazida Labesfal indications
Hypertension
Losartan + Hidroclorotiazida Labesfal® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Losartan (Losartan + Hidroclorotiazida Labesfal) and Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal).
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.
Losartan + Hidroclorotiazida Labesfal may be administered with other antihypertensive agents.
Hypertensive Patients With Left Ventricular Hypertrophy
Losartan + Hidroclorotiazida Labesfal is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients.
How should I use Losartan + Hidroclorotiazida Labesfal?
Use Losartan + Hidroclorotiazida Labesfal as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Losartan + Hidroclorotiazida Labesfal. Talk to your pharmacist if you have questions about this information.
- Take Losartan + Hidroclorotiazida Labesfal by mouth with or without food.
- Drinking extra fluids while you are taking Losartan + Hidroclorotiazida Labesfal is recommended. Check with your doctor for instructions.
- Losartan + Hidroclorotiazida Labesfal may increase the amount of urine or cause you to urinate more often when you first start taking it. To keep this from disturbing your sleep, try to take your dose before 6 pm.
- If you take cholestyramine or colestipol, ask your doctor or pharmacist how to take it with Losartan + Hidroclorotiazida Labesfal.
- Continue to take Losartan + Hidroclorotiazida Labesfal even if you feel well. Do not miss any doses.
- If you miss a dose of Losartan + Hidroclorotiazida Labesfal, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Losartan + Hidroclorotiazida Labesfal.
Uses of Losartan + Hidroclorotiazida Labesfal in details
Use: Labeled Indications
Hypertension: Management of hypertension.
Hypertension with left ventricular hypertrophy: To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH). Evidence suggests that this benefit does not apply to black patients.
Losartan + Hidroclorotiazida Labesfal description
Each tablet contains Losartan (Losartan + Hidroclorotiazida Labesfal) potassium 50 or 100 mg and Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) 12.5 mg.
Losartan (Losartan + Hidroclorotiazida Labesfal) Potassium: Losartan (Losartan + Hidroclorotiazida Labesfal) potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol monopotassium salt.
Its empirical formula is C22H22ClKN6O.
Losartan (Losartan + Hidroclorotiazida Labesfal) potassium is a white to off-white free-flowing crystalline powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents eg, acetonitrile and methyl ethyl ketone.
Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of Losartan (Losartan + Hidroclorotiazida Labesfal).
Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal): Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.
Its empirical formula is C7H8ClN3O4S2.
It is a white, or practically white, crystalline powder with a molecular weight of 297.74, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.
Losartan + Hidroclorotiazida Labesfal dosage
Hypertension
The usual starting dose of Losartan + Hidroclorotiazida Labesfal is 50/12.5 (Losartan (Losartan + Hidroclorotiazida Labesfal) 50 mg/Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) 12.5 mg) once daily. The dosage can be increased after 3 weeks of therapy to a maximum of 100/25 (Losartan (Losartan + Hidroclorotiazida Labesfal) 100 mg/Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) 25 mg) once daily as needed to control blood pressure.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartan + Hidroclorotiazida Labesfal) 50 mg monotherapy with Losartan + Hidroclorotiazida Labesfal 50/12.5 once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dosage may be increased to two tablets of Losartan + Hidroclorotiazida Labesfal 50/12.5 once daily or one tablet of Losartan + Hidroclorotiazida Labesfal 100/25 once daily.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartan + Hidroclorotiazida Labesfal) 100 mg monotherapy with Losartan + Hidroclorotiazida Labesfal 100/12.5 (Losartan (Losartan + Hidroclorotiazida Labesfal) 100 mg/Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) 12.5 mg) once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartan + Hidroclorotiazida Labesfal 50/12.5 once daily or one tablet of Losartan + Hidroclorotiazida Labesfal 100/25 once daily.
Initiate a patient whose blood pressure is inadequately controlled with Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) 25 mg once daily, or is controlled but who experiences hypokalemia with this regimen, on Losartan + Hidroclorotiazida Labesfal 50/12.5 once daily, reducing the dose of Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) without reducing the overall expected antihypertensive response. Evaluate the clinical response to Losartan + Hidroclorotiazida Labesfal 50/12.5 and, if blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartan + Hidroclorotiazida Labesfal 50/12.5 once daily or one tablet of Losartan + Hidroclorotiazida Labesfal 100/25 once daily.
Hypertensive Patients with Left Ventricular Hypertrophy
In patients whose blood pressure is not adequately controlled on 50 mg Losartan (Losartan + Hidroclorotiazida Labesfal) potassium, initiate treatment with Losartan + Hidroclorotiazida Labesfal 50/12.5. If additional blood pressure reduction is needed, increase the dose to Losartan + Hidroclorotiazida Labesfal 100/12.5, followed by Losartan + Hidroclorotiazida Labesfal 100/25. For further blood pressure reduction add other antihypertensives.
Losartan + Hidroclorotiazida Labesfal interactions
See also:
What other drugs will affect Losartan + Hidroclorotiazida Labesfal?
Agents Increasing Serum Potassium
Coadministration of Losartan (Losartan + Hidroclorotiazida Labesfal) with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
Lithium
Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics. Monitor lithium levels in patients receiving Losartan + Hidroclorotiazida Labesfal and lithium.
Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors
Losartan (Losartan + Hidroclorotiazida Labesfal) Potassium
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including Losartan (Losartan + Hidroclorotiazida Labesfal)) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Losartan (Losartan + Hidroclorotiazida Labesfal) and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including Losartan (Losartan + Hidroclorotiazida Labesfal), may be attenuated by NSAIDs, including selective COX-2 inhibitors.
Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal)
The administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Losartan + Hidroclorotiazida Labesfal and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.
In patients receiving diuretic therapy, coadministration of NSAIDs with angiotensin receptor blockers, including Losartan (Losartan + Hidroclorotiazida Labesfal), may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal), Losartan (Losartan + Hidroclorotiazida Labesfal), and NSAID therapy.
Dual Blockade Of The Renin-Angiotensin System (RAS)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of Losartan (Losartan + Hidroclorotiazida Labesfal) therapy and followed them for a median of 2.2 years. Patients receiving the combination of Losartan (Losartan + Hidroclorotiazida Labesfal) and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end-stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.
Closely monitor blood pressure, renal function, and electrolytes in patients on Losartan + Hidroclorotiazida Labesfal and other agents that affect the RAS.
Do not coadminister aliskiren with Losartan + Hidroclorotiazida Labesfal in patients with diabetes. Avoid use of aliskiren with Losartan + Hidroclorotiazida Labesfal in patients with renal impairment (GFR < 60 mL/min).
The Use Of Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) With Other Drugs
When administered concurrently, the following drugs may interact with thiazide diuretics :
Antidiabetic drugs (oral agents and insulin) — dosage adjustment of the antidiabetic drug may be required.
Cholestyramine and colestipol resins — Absorption of Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Stagger the dosage of Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) and the resin such that Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.
Losartan + Hidroclorotiazida Labesfal side effects
See also:
What are the possible side effects of Losartan + Hidroclorotiazida Labesfal?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Losartan (Losartan + Hidroclorotiazida Labesfal) potassium-Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) has been evaluated for safety in 858 patients treated for essential hypertension and 3889 patients treated for hypertension and left ventricular hypertrophy. Most adverse reactions have been mild and transient in nature and have not required discontinuation of therapy. In controlled clinical trials, discontinuation of therapy due to clinical adverse events was required in only 2.8% and 2.3% of patients treated with the combination and placebo, respectively.
In these double-blind controlled clinical trials, adverse reactions occurring in greater than 2% of subjects treated with Losartan (Losartan + Hidroclorotiazida Labesfal)-Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) and at a greater rate than placebo were: back pain (2.1% vs 0.6%), dizziness (5.7% vs 2.9%), and upper respiratory infection (6.1% vs 4.6%).
The following additional adverse reactions have been reported in clinical trials with Losartan + Hidroclorotiazida Labesfal and/or the individual components:
Blood and the lymphatic system disorders: Anemia, aplastic anemia, hemolytic anemia, leukopenia, agranulocytosis.
Metabolism and nutrition disorders: Anorexia, hyperglycemia, hyperuricemia, electrolyte imbalance including hyponatremia and hypokalemia.
Psychiatric disorders: Insomnia, restlessness.
Nervous system disorders: Dysgeusia, headache, migraine, paraesthesias.
Eye disorders: Xanthopsia, transient blurred vision.
Cardiac disorders: Palpitation, tachycardia.
Vascular disorders: Dose-related orthostatic effects, necrotizing angiitis (vasculitis, cutaneous vasculitis).
Respiratory, thoracic and mediastinal disorders: Nasal congestion, pharyngitis, sinus disorder, respiratory distress (including pneumonitis and pulmonary edema).
Gastrointestinal disorders: Dyspepsia, abdominal pain, gastric irritation, cramping, diarrhea, constipation, nausea, vomiting, pancreatitis, sialoadenitis.
Hepato-biliary disorders: Jaundice (intrahepatic cholestatic jaundice).
Skin and subcutaneous tissue disorders: Rash, pruritus, purpura, toxic epidermal necrolysis, urticaria, photosensitivity, cutaneous lupus erythematosus.
Musculoskeletal and connective tissue disorders: Muscle cramps, muscle spasm, myalgia, arthralgia.
Renal and urinary disorders: Glycosuria, renal dysfunction, interstitial nephritis, renal failure.
Reproductive system and breast disorders: Erectile dysfunction/impotence.
General disorders and administration site conditions: Chest pain, edema/swelling, malaise, fever, weakness.
Investigations: Liver function abnormalities.
Cough
Persistent dry cough has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy. Two prospective, parallel-group, double-blind, randomized, controlled trials were conducted to assess the effects of Losartan (Losartan + Hidroclorotiazida Labesfal) on the incidence of cough in hypertensive patients who had experienced cough while receiving ACE-inhibitor therapy. Patients who had typical ACE-inhibitor cough when challenged with lisinopril, whose cough disappeared on placebo, were randomized to Losartan (Losartan + Hidroclorotiazida Labesfal) 50 mg, lisinopril 20 mg, or either placebo (one study, n=97) or 25 mg Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) (n=135). The double-blind treatment period lasted up to 8 weeks. The incidence of cough is shown in Table 1 below.
| |||
| Study 1* | HCTZ | Losartan (Losartan + Hidroclorotiazida Labesfal) | Lisinopril |
| Cough | 25% | 17% | 69% |
| Study 2† | Placebo | Losartan (Losartan + Hidroclorotiazida Labesfal) | Lisinopril |
| Cough | 35% | 29% | 62% |
These studies demonstrate that the incidence of cough associated with Losartan (Losartan + Hidroclorotiazida Labesfal) therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal) or placebo therapy.
Cases of cough, including positive re-challenges, have been reported with the use of Losartan (Losartan + Hidroclorotiazida Labesfal) in postmarketing experience.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Losartan + Hidroclorotiazida Labesfal. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
Digestive: Hepatitis has been reported rarely in patients treated with Losartan (Losartan + Hidroclorotiazida Labesfal).
Hematologic: Thrombocytopenia.
Hypersensitivity: Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported rarely in patients treated with Losartan (Losartan + Hidroclorotiazida Labesfal); some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Vasculitis, including Henoch-Schönlein purpura, has been reported with Losartan (Losartan + Hidroclorotiazida Labesfal). Anaphylactic reactions have been reported.
Musculoskeletal: rhabdomyolysis
Skin: Erythroderma
Losartan + Hidroclorotiazida Labesfal contraindications
See also:
What is the most important information I should know about Losartan + Hidroclorotiazida Labesfal?
Hypersensitivity to Losartan (Losartan + Hidroclorotiazida Labesfal), sulphonamide-derived substances (as Hydrochlorothiazide (Losartan (Losartan + Hidroclorotiazida Labesfal) + Hidroclorotiazida Labesfal)) or to any of the excipients of Losartan + Hidroclorotiazida Labesfal.
Therapy resistant hypokalemia or hypercalcemia; severe hepatic impairment; cholestasis and biliary obstructive disorders; refractory hyponatremia; symptomatic hyperuricemia/gout; 2nd and 3rd trimester of pregnancy; lactation; severe renal impairment (ie, creatinine clearance <30 mL/min); anuria.
Excipient: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Losartan + Hidroclorotiazida Labesfal.
Use in lactation: It is not known whether Losartan (Losartan + Hidroclorotiazida Labesfal) is excreted in human milk. However, Losartan (Losartan + Hidroclorotiazida Labesfal) is excreted in the milk of lactating rats. Because no information is available regarding the use of Losartan (Losartan + Hidroclorotiazida Labesfal) during breastfeeding, Losartan (Losartan + Hidroclorotiazida Labesfal) is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.
Thiazides pass into human milk and may inhibit lactation. Because of the potential for adverse effects on the nursing infant, Losartan (Losartan + Hidroclorotiazida Labesfal)/HCTZ is contraindicated during breastfeeding.
Active ingredient matches for Losartan + Hidroclorotiazida Labesfal:
Hydrochlorothiazide/Losartan in Portugal.
List of Losartan + Hidroclorotiazida Labesfal substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Losartan; Hydrochlorothiazide | |
| Tablet; Oral; Losartan Potassium 50 mg; Hydrochlorothiazide 12.5 mg | |
| Losartana + Hidroclorotiazida Sandoz (Brazil) | |
| Losartana Potássica + HCT Biosintética (Brazil) | |
| Losartana Potássica + HCT EMS (Brazil) | |
| Losartana Potássica + HCT Eurofarma (Brazil) | |
| Losartana Potássica + HCT Gen.Germed (Brazil) | |
| Losartana Potássica + HCT Gen.Legrand (Brazil) | |
| Losartana Potássica + HCT Medley (Brazil) | |
| Losartana Potássica + HCT Pharlab (Brazil) | |
| Losartankalium/HCT CF (Netherlands) | |
| Losartankalium/HCT Jubilant (Netherlands) | |
| Losartankalium/HCT PCH (Netherlands) | |
| Losartankalium/HCT Ranbaxy (Netherlands) | |
| Losartankalium/HCT ratiopharm (Netherlands) | |
| Losartankalium/HCT Teva (Netherlands) | |
| Losartankalium/HCT Xiromed (Netherlands) | |
| Losartankalium/hydrochloorthiazide A (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Apotex (Netherlands) | |
| Losartankalium/hydrochloorthiazide Auro (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Bluefish (Netherlands) | |
| Losartankalium/hydrochloorthiazide Farmaprojects (Netherlands) | |
| Losartankalium/hydrochloorthiazide IPCA (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Mylan (Netherlands) | |
| Losartankalium/hydrochlorthiazid Actavis (Denmark) | |
| Losartankalium/hydrochlorthiazid Amneal (Denmark) | |
| Losartankalium/hydrochlorthiazid Krka (Denmark) | |
| Losartankalium/Hydrochlorthiazid Medical Valley (Denmark) | |
| Losartankalium/hydrochlorthiazid Teva (Denmark) | |
| Losartar-H (India) | |
| Losartar-H Losartan K , Hydrochlorothiazide TAB / 10 (Shrrishti HC) | $ 0.60 |
| 10's (Shrrishti HC) | $ 0.60 |
| LOSARTAR-H tab 10's (Shrrishti HC) | $ 0.60 |
| Losartas HT (Peru) | |
| Losartas HT Hydrochlorothiazide 12.5mg, Losartan K 50mg TAB / 7 | $ 0.69 |
| Losartas HT Tablet (Intas Pharmaceuticals Ltd) | $ 0.11 |
| Losarteg HCT (El Salvador) | |
| Losartic HC (Slovenia) | |
| Losartic Plus (Croatia (Hrvatska), Serbia) | |
| Losartil-Plus (Turkey) | |
| Losasis-H | |
| Losasis-H 50mg/12.5mg Tablet (CHS Formulations) | $ 0.08 |
| Losastal-H Tablet | |
| Losastal-H Tablet (Stallion Laboratories Pvt Ltd) | $ 0.08 |
| LOSASUN HT | |
| LOSASUN HT TABLET 1 strip / 10 tablets each (Sunij Pharma Pvt Ltd) | $ 0.35 |
| LOSATAN H | |
| LOSATAN H TABLET 1 strip / 10 tablets each (Biochem Pharmaceutical Industries) | $ 0.60 |
| Losatan Hz (Bangladesh) | |
See 1294 substitutes for Losartan + Hidroclorotiazida Labesfal | |
References
- DailyMed. "AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "losartan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Losartan + Hidroclorotiazida Labesfal are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Losartan + Hidroclorotiazida Labesfal. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
